CLDX Relative Valuation
CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLDX is overvalued; if below, it's undervalued.
Historical Valuation
Celldex Therapeutics Inc (CLDX) is now in the Fair zone, suggesting that its current forward PS ratio of 372.11 is considered Fairly compared with the five-year average of -13.66. The fair price of Celldex Therapeutics Inc (CLDX) is between 16.06 to 44.77 according to relative valuation methord.
Relative Value
Fair Zone
16.06-44.77
Current Price：22.79
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.17
P/B
Median3y
4.06
Median5y
4.29
-11.43
FCF Yield
Median3y
-7.10
Median5y
-6.26
Competitors Valuation Multiple
The average P/S ratio for CLDX's competitors is 239.17, providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of 372.11, which is 55.58% above the industry average. Given its robust revenue growth of 345.51%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Celldex Therapeutics Inc (CLDX) currently overvalued or undervalued?
What is Celldex Therapeutics Inc (CLDX) fair value?
How does CLDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Celldex Therapeutics Inc (CLDX) as of Jul 19 2025?
What is the current FCF Yield for Celldex Therapeutics Inc (CLDX) as of Jul 19 2025?
What is the current Forward P/E ratio for Celldex Therapeutics Inc (CLDX) as of Jul 19 2025?